Trending Topic

virus closeup, contagious pathogen. Monkey pox virus closeup, contagious pathogen, infectious zoonotic disease
7 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

A double-stranded DNA virus of the Orthopoxvirus family, mpox (formerly monkeypox), continues to infect people daily, following the 2022 global outbreak.1 Two clades (clade 1 and clade 2) have been identified, with the 2022 outbreak caused by a subclade of clade 2, referred to as clade 2b.2 Comparatively, clade 1 leads to a more severe disease state and greater […]

touchLearning Activities

Education, Conference Coverage and Articles

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Dr Clarissa Melo Czekster is a rising star in the field of enzymology and bacterial pathogenesis. In this Q&A, she reflects on her early inspirations, key mentors, and the molecular curiosity that drives her work in infectious diseases. From childhood experiments to developing novel antibiofilm tools, her career blends biochemical precision with a passion for collaborative science.

Mark CompleteCompleted
BookmarkBookmarked

"Even with intensive support, short-cycle therapy did not match the effectiveness of daily treatment in adolescents." - Dr Adeodata R. Kekitiinwa   Short-cycle therapy (SCT) has previously shown promise in maintaining viral suppression among young people living with HIV. In ...

Mark CompleteCompleted
BookmarkBookmarked

A resident of northern Arizona, USA, has died after contracting pneumonic plague, a rare but highly serious form of the disease caused by the bacterium Yersinia pestis, according to a statement from the Coconino County Health and Human Services (CCHHS). This is the first confirmed plague-related fatality in the county in several years and has prompted increased public health monitoring and community awareness efforts.

Mark CompleteCompleted
BookmarkBookmarked

Despite the availability of curative therapies, hepatitis C virus (HCV) remains a global health challenge.

In this Q&A, you will learn:

  • Current HCV treatment standards and remaining barriers to universal access.
  • Practical strategies to support adherence and follow-up in underserved groups.
  • Key considerations when treating patients with HIV co-infection or cirrhosis.
  • The importance of prevention and the role of vaccines in future HCV control.

Mark CompleteCompleted
BookmarkBookmarked

As touchINFECTIOUS DISEASES approaches 20 years of providing education for busy infectious disease specialists, we are looking to the future—and it certainly looks bright!

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

We are delighted to welcome Dr Dariusz Hareza to the touchINFECTIOUS DISEASES Editorial Board. Dr Hareza is an Assistant Professor of Medicine (Infectious Diseases) at Northwestern University Feinberg School of Medicine, Chicago, IL, USA. He brings to the board a ...

Mark CompleteCompleted
BookmarkBookmarked

The US Food and Drug Administration (FDA) has expanded the indication of the pangenotypic direct-acting antiviral (DAA) combination, glecaprevir/pibrentasvir (Mavyret®; AbbVie Inc., North Chicago, IL, USA), to include the treatment of acute hepatitis C virus (HCV) infection in adults ...

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

Mark CompleteCompleted
BookmarkBookmarked

The World Vaccine Congress Washington 2025, 21-24 April 2025, delivered another landmark year, bringing together more than 4,000 global stakeholders from biotechnology, pharmaceuticals, government, academia and the broader global health ecosystem. The event reinforced its standing as an influential and collaborative forum in ...

Mark CompleteCompleted
BookmarkBookmarked

We are delighted to announce that Dr. Ikechukwu Benjamin Moses has joined the touchINFECTIOUS DISEASES Editorial Board! “I strongly believe that this platform will greatly contribute in promoting science to a broader audience with strong societal impact.” Dr Moses brings ...

Mark CompleteCompleted
BookmarkBookmarked

The ESCMID Global Congress 2025 brought together world-leading researchers and clinicians to present practice-changing updates in infectious disease management. This article distils five critical insights from interviews and landmark trial results, covering innovations in antimicrobial therapy, fungal infections, resistance surveillance and ...

Developed by Touch
Coverage from: Key congresses in 2025

The RIO study tested whether broadly neutralizing antibodies could safely replace daily HIV therapy. In a rigorously designed trial, 75% of participants maintained viral suppression for 20 weeks after stopping antiretrovirals. The findings mark a pivotal step toward potential HIV remission and more flexible treatment strategies.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Developed by Touch
Coverage from: Key congresses in 2025

Dr. Sarah Fidler discusses the challenges of lifelong antiretroviral therapy for HIV and the need for alternative approaches. She highlights broadly neutralising antibodies (bNAbs) as a promising strategy that targets the virus and dormant infected cells, potentially enabling longer-term control by harnessing the immune system’s memory without daily medication.

Mark CompleteCompleted
BookmarkBookmarked

Dr. Ikechukwu B. Moses, winner of the ESCMID Global 2025 Emerging Young Investigator Award, explores antimicrobial resistance through a One Health lens. His work spans zoonotic pathogen transmission, bacteriophage therapy, and AI-driven genomic research, aiming to reduce antibiotic reliance and translate lab-based innovations into scalable, real-world clinical and veterinary solutions.

Mark CompleteCompleted
BookmarkBookmarked

Dr Dariusz Hareza reflects on ESCMID Global 2025, highlighting its international scope, informal collaboration, and key themes in antimicrobial resistance. He discusses impactful sessions on global surveillance, Kazakhstan’s primary care initiatives, and novel approaches like CRISPR and AI, all pointing toward an innovative and integrated future in infectious diseases.

Mark CompleteCompleted
BookmarkBookmarked

The US Food and Drug Administration (FDA) has approved the first virus-like particle (VLP) chikungunya vaccine PXVX0317 (VIMKUNYA™), for individuals aged 12 years and older, with Bavarian Nordic recently announcing its commercial launch.1,2 This approval addresses a critical unmet need for ...

Load More...
touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES

Register Now!

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

  • Save your progress for video
  • Keep track of your CME credits
  • Add personalised learning notes
  • Receive updates from course leaders and faculty
  • Be the first to hear about new and exciting interactive learning opportunities
Close Popup